Olmeslide AZ 8-40 Tablet contains Olmesartan Medoxomil 40mg, an angiotensin II receptor blocker that reduces vasoconstriction and prevents fluid retention, combined with Azelnidipine 8mg, a long-acting calcium channel blocker that enhances vascular relaxation. This combination provides potent and sustained blood pressure reduction, suitable for patients requiring higher-dose therapy.
Clinically, it is indicated for essential hypertension, particularly in patients who do not achieve adequate control with lower-dose combinations or monotherapy. The dual action ensures effective systolic and diastolic blood pressure management, minimizing cardiovascular risk.
The tablet formulation ensures consistent bioavailability, accurate dosing, and reliable therapeutic outcomes, making it suitable for hospital pharmacies, cardiology clinics, outpatient departments, and specialty pharmacies. Once-daily dosing supports better patient adherence and convenient therapy.
Olmeslide AZ 8-40 Tablet helps in reducing cardiovascular complications, protecting target organs, stabilizing hemodynamics, and improving long-term hypertension management. With its proven efficacy and safety under medical supervision, it is a trusted option for intensive antihypertensive therapy.